OncoMatch/Clinical Trials/NCT07043270
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
Is NCT07043270 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nab-paclitaxel + Gemcitabine and modified FOLFIRINOX (mFOLFIRINOX) for pancreas adenocarcinoma.
Treatment: Nab-paclitaxel + Gemcitabine · modified FOLFIRINOX (mFOLFIRINOX) — The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: BRCA1 mutation
Excluded: BRCA2 mutation
Excluded: DPYD poor metabolizer genotype
Excluded: PALB2 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Any prior receipt of chemotherapy or radiation therapy for PDAC.
Cannot have received: radiation therapy
Any prior receipt of chemotherapy or radiation therapy for PDAC.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) < 2,500/mm3; Platelet count < 100,000/mm3; Hemoglobin < 7 g/dL [excluded]
Kidney function
Creatinine > 1.5 x upper limit of normal (ULN) [excluded]
Liver function
Total bilirubin > 1.5 x ULN; AST/ALT > 5 x ULN [excluded]
Any of the following baseline laboratory abnormalities: Absolute neutrophil count (ANC) < 2,500/mm3; Platelet count < 100,000/mm3; Hemoglobin < 7 g/dL; Creatinine > 1.5 x upper limit of normal (ULN); Total bilirubin > 1.5 x ULN; AST/ALT > 5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify